BioCentury | Jan 31, 2020
Distillery Therapeutics

CLEC14A-positive stem cell transplants for muscle regeneration

DISEASE CATEGORY: Musculoskeletal INDICATION: Musculoskeletal Transplantation with muscle-derived CLEC14A-positive stem cells could regenerate muscle following injury, despite lacking expression of known myogenic regulator PAX7. The myogenic cells were isolated from muscle fiber fragments that underwent...
BioCentury | Jun 1, 2019
Product Development

ASCO 2019 abstracts show solid tumor race heating up among bispecifics and CAR Ts

While strong progress in CAR T therapies will again feature at this year’s ASCO meeting, bispecific antibodies are having a moment -- making more inroads into solid tumors than CAR Ts and branching out via...
BioCentury | Jul 25, 2018
Distillery Techniques

Disease models

...TECHNOLOGY: Transgenics and knockouts Zebrafish expressing human PAX3 and FOXO1 could be used to screen therapies...
...Next steps could include using the model to screen therapies. DESCRIPTION: Zebrafish expressing human paired box 3 (PAX3...
...Medical Center, Dallas, Texas email: Mark Zipkin University of Texas Southwestern Medical Center Forkhead box O1 (FOXO1) Paired box 3 (PAX3) Sarcoma rhabdomyosarcoma...
BioCentury | Jul 10, 2018
Distillery Therapeutics


...Cell culture and mouse studies suggest combining Mekinist trametinib with IGF1R inhibitors could help treat PAX3-PAX7... Phase I testing for solid tumors. TARGET/MARKER/PATHWAY: Insulin-like growth factor-1 receptor (IGF1R; CD221); paired box 3 (PAX3...
...factor-1 (IGF-1) receptor (IGF1R) (CD221) MAP kinase kinase 1 (MAP2K1) (MEK1) MAP kinase kinase 2 (MAP2K2) (MEK2) Paired box 3 (PAX3) Paired...
BioCentury | Apr 10, 2018
Preclinical News

Researchers identify coding, non-coding driver mutations in MM

Scientists from the Institute of Cancer Research (London, U.K.) identified coding and non-coding driver mutations involved in newly diagnosed multiple myeloma, suggesting the genes could be targeted to treat the disease. The research was published...
BioCentury | Dec 22, 2016
Translation in Brief

Pin the tail

...a 2012 Cell Stem Cell study, Rando’s team showed mRNA encoding the transcription factor paired box 3 (PAX3...
BioCentury | Dec 6, 2016
Distillery Therapeutics


INDICATION: Sarcoma Cell culture studies suggest inhibiting CHD4 could help treat PAX-FOX1 fusion gene -positive rhabdomyosarcomas. In two human rhabdomyosarcoma cell lines positive for the PAX-FOX1 fusion oncogene, shRNA targeting CHD4 decreased cell numbers and...
BioCentury | Jun 16, 2016
Emerging Company Profile

No cells left behind

Although transplantation of human islets from donated pancreatic tissue is well known to restore insulin production in Type I diabetes patients, there is a severe shortage of donor tissue. Islexa Ltd. has developed a way...
BioCentury | Apr 14, 2016
Product R&D

AACR by the numbers

...genetic screens , and mouse studies suggest silencing or depleting CHD4 could help treat paired box 3 (PAX3)-forkhead...
BioCentury | Dec 14, 2015
Product Development

Following CoMMpass

Amidst a flood of promising data for hot targets, indications and technologies at this year's American Society of Hematology meeting, one collection of presentations stands out not only for the wide-reaching implications of their data,...
Items per page:
1 - 10 of 29